Control Bionics Ltd. ( (AU:CBL) ) just unveiled an announcement.
Control Bionics Limited has announced the appointment of Dr. Stephanie Phillips to its Board of Directors, bringing her extensive experience in anaesthesia and critical care to the company. Her expertise is expected to significantly contribute to Control Bionics’ expansion into new markets in assistive communication, rehabilitation, and health diagnostics. Concurrently, the company announced the resignation of its founder, Peter Ford, from the Board, effective March 31, 2025. Ford’s pioneering work led to the development of the NeuroNode technology, which has been transformative in the assistive technology sector. While stepping down, Ford remains a significant shareholder, ensuring his continued influence on the company’s future.
More about Control Bionics Ltd.
Control Bionics is a medical device company focused on assisting patients with compromised communication abilities due to conditions like Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Their core technology, the NeuroNode, is a wireless wearable device that detects signals from the brain to muscles, enabling communication through EMG output. This technology integrates touch, eye gaze, and NeuroNode control to enhance patient communication with speed and reduced fatigue.
YTD Price Performance: -43.33%
Average Trading Volume: 152,923
Technical Sentiment Signal: Buy
Current Market Cap: A$11.78M
See more insights into CBL stock on TipRanks’ Stock Analysis page.